

Protocol

# Protocol for Combined Analysis of FOXFIRE, SIRFLOX, and FOXFIRE-Global Randomized Phase III Trials of Chemotherapy +/- Selective Internal Radiation Therapy as First-Line Treatment for Patients With Metastatic Colorectal Cancer

Pradeep S Virdee<sup>1</sup>, BSc, MSc; Joanna Moschandreass<sup>1</sup>, BSc, MSc, PhD; Val Gebbski<sup>2</sup>, MStat; Sharon B Love<sup>1</sup>, BSc; E Anne Francis<sup>3</sup>, BSc, D. Phil; Harpreet S Wasan<sup>4</sup>, MBBS, FRCP; Guy van Hazel<sup>5</sup>, MBBS, FRACP, FRCP; Peter Gibbs<sup>6</sup>, MBBS, FRACP, MD; Ricky A Sharma<sup>7,8</sup>, MD, PhD

<sup>1</sup>Centre for Statistics in Medicine, University of Oxford, Oxford, United Kingdom

<sup>2</sup>NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia

<sup>3</sup>Oncology Clinical Trials Office, Department of Oncology, University of Oxford, Oxford, United Kingdom

<sup>4</sup>Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, United Kingdom

<sup>5</sup>University of Western Australia, Perth, Australia

<sup>6</sup>Western Hospital, Footscray, Victoria, Australia

<sup>7</sup>National Institute for Health Research University College London Hospitals Biomedical Research Centre, London, United Kingdom

<sup>8</sup>Cancer Research United Kingdom—Medical Research Council Oxford Institute for Radiation Oncology, University of Oxford, Oxford, United Kingdom

**Corresponding Author:**

Ricky A Sharma, MD, PhD

National Institute for Health Research University College London Hospitals Biomedical Research Centre

UCL Cancer Institute

University College London

London,

United Kingdom

Phone: 44 020 3108 2212

Fax: 44 020 7679 6817

Email: [ricky.sharma@oncology.ox.ac.uk](mailto:ricky.sharma@oncology.ox.ac.uk)

## Abstract

**Background:** In colorectal cancer (CRC), unresectable liver metastases are associated with a poor prognosis. The FOXFIRE (an open-label randomized phase III trial of 5-fluorouracil, oxaliplatin, and folinic acid +/- interventional radioembolization as first-line treatment for patients with unresectable liver-only or liver-predominant metastatic colorectal cancer), SIRFLOX (randomized comparative study of FOLFOX6m plus SIR-Spheres microspheres versus FOLFOX6m alone as first-line treatment in patients with nonresectable liver metastases from primary colorectal carcinoma), and FOXFIRE-Global (assessment of overall survival of FOLFOX6m plus SIR-Spheres microspheres versus FOLFOX6m alone as first-line treatment in patients with nonresectable liver metastases from primary colorectal carcinoma in a randomized clinical study) clinical trials were designed to evaluate the efficacy and safety of combining first-line chemotherapy with selective internal radiation therapy (SIRT) using yttrium-90 resin microspheres, also called transarterial radioembolization.

**Objective:** The aim of this analysis is to prospectively combine clinical data from 3 trials to allow adequate power to evaluate the impact of chemotherapy with SIRT on overall survival.

**Methods:** Eligible patients are adults with histologically confirmed CRC and unequivocal evidence of liver metastases which are not treatable by surgical resection or local ablation with curative intent at the time of study entry. Patients may also have limited extrahepatic metastases. Final analysis will take place when all participants have been followed up for a minimum of 2 years.

**Results:** Efficacy and safety estimates derived using individual participant data (IPD) from SIRFLOX, FOXFIRE, and FOXFIRE-Global will be pooled using 2-stage prospective meta-analysis. Secondary outcome measures include progression-free survival (PFS), liver-specific PFS, health-related quality of life, response rate, resection rate, and adverse event profile. The large

study population will facilitate comparisons of low frequency adverse events and allow for more robust safety analyses. The potential treatment benefit in those patients who present with disease confined to the liver will be investigated using 1-stage IPD meta-analysis. Efficacy will be analyzed on an intention-to-treat basis.

**Conclusions:** This analysis will assess the impact of SIRT combined with chemotherapy on overall survival in the first-line treatment of metastatic CRC. If positive, the results will change the standard of care for this disease.

**Trial Registration:** FOXFIRE ISRCTN Registry ISRCTN83867919; <http://www.isrctn.com/ISRCTN83867919> (Archived by WebCite at <http://www.webcitation.org/6oN7axrvA>). SIRFLOX ClinicalTrials.gov NCT00724503; <https://clinicaltrials.gov/ct2/show/NCT00724503> (Archived by WebCite at <http://www.webcitation.org/6oN7IEGbD>). FOXFIRE-Global ClinicalTrials.gov NCT01721954; <https://clinicaltrials.gov/ct2/show/NCT01721954> (Archived by WebCite at <http://www.webcitation.org/6oN7vvQvG>).

(*JMIR Res Protoc* 2017;6(3):e43) doi:[10.2196/resprot.7201](https://doi.org/10.2196/resprot.7201)

## KEYWORDS

colorectal neoplasms; liver; neoplasm metastasis; radiation oncology; survival analysis; meta-analysis

## Introduction

The 5-year overall survival (OS) of metastatic colorectal cancer (mCRC) patients, who constitute 21% of all CRC diagnoses, is approximately 13% [1]. The liver is the dominant site of metastases in CRC; liver metastases are the most common cause of death for patients with CRC [2,3]. To improve outcomes in mCRC, efforts have been made to increase the proportion of patients eligible for surgical resection, which is currently 20% [4-8]. The use of down-staging neoadjuvant chemotherapy in clinical studies has suggested that 10%-20% of patients with inoperable liver disease may be converted to candidates for curative resection [9]. Furthermore, a statistical correlation between tumor response and resection rates has been found across clinical studies [10].

Among the liver-directed therapies that may control liver metastases, selective internal radiation therapy (SIRT) is one option for patients with liver-only or liver-dominant disease [11,12]. SIR-Spheres (Sirtex Medical Limited) containing the  $\beta$ -emitter, yttrium-90, are delivered into the arterial supply of the liver under fluoroscopic guidance. The delivery of the resin microspheres into branches of the hepatic artery, which supplies the majority of blood to liver tumors, results in selective targeting of the tumor by high-dose radiotherapy, whereas the healthy liver is supplied predominantly by the portal venous system and is therefore relatively spared from radiation treatment [12].

The FOXFIRE (an open-label randomized phase III trial of 5-fluorouracil, oxaliplatin, and folinic acid +/- interventional radioembolization as first-line treatment for patients with unresectable liver-only or liver-predominant metastatic colorectal cancer), SIRFLOX (randomized comparative study of FOLFOX6m plus SIR-Spheres microspheres versus FOLFOX6m alone as first-line treatment in patients with unresectable liver metastases from primary colorectal carcinoma), and FOXFIRE-Global (assessment of overall survival of FOLFOX6m plus SIR-Spheres microspheres versus

FOLFOX6m alone as first-line treatment in patients with unresectable liver metastases from primary colorectal carcinoma in a randomized clinical study) clinical trials were designed to study SIRT in combination with chemotherapy, specifically the modified fluorouracil, leucovorin, and oxaliplatin (FOLFOX) regimen, compared with FOLFOX alone as first-line therapy for mCRC [13,14]. Eligibility criteria and trial designs were similar for the 3 trials so that they could be prospectively combined. The primary and some secondary endpoints of SIRFLOX have been published, representing the largest published, randomized, multicenter trial of any liver-directed therapy in patients with mCRC [15]. The results showed increased progression-free survival (PFS) in the liver with the addition of SIRT but no effect of SIRT on overall PFS [15].

The primary objective of the combined analysis is to report the planned meta-analysis (MA) of individual participant data (IPD) from the FOXFIRE, SIRFLOX, and FOXFIRE-Global studies for the primary endpoint, OS, and for secondary outcomes including PFS, liver-specific PFS, quality of life measures, response rate, resection rate, and adverse event profile. The IPD-MA will assess the treatment effects on clinical outcomes in the entire subject group and in key subgroups.

## Methods

### Study Design

As the results on survival benefits for each of the 3 studies are still blinded, the statistical design is a prospective MA based on randomized IPD from the FOXFIRE, SIRFLOX, and FOXFIRE-Global clinical trials.

The protocols of the FOXFIRE [13] and SIRFLOX [14] trials have been previously published. All 3 clinical trials were open-label multicenter, randomized, 2-arm trials comparing chemotherapy plus SIRT with chemotherapy alone as first-line treatment for patients with mCRC. The design of the 3 trials is summarized in [Table 1](#) and [Figure 1](#).

**Table 1.** Characteristics of studies included in the meta-analysis: FOXFIRE [13], SIRFLOX [14], and FOXFIRE-Global.


	FOXFIRE <sup>a</sup>	SIRFLOX <sup>b</sup>	FOXFIRE-Global <sup>c</sup>
Start of recruitment	Nov 13, 2009	Oct 11, 2006	May 20, 2013
End of recruitment	Oct 31, 2014	Apr 25, 2013	Dec 23, 2014
End of follow-up	Oct 31, 2016	Apr 25, 2018	Dec 23, 2019
Number of recruiting centers	28	87	69
Primary objective	Overall survival	Progression-free survival	Overall survival
Secondary objectives	Progression-free survival	Overall survival	Progression-free survival
	Progression-free survival in the liver	Progression-free survival in the liver	Progression-free survival in the liver
	Toxicity and safety	Toxicity and safety	Toxicity and safety
	Tumor response rate	Tumor response rate	Tumor response rate
	Quality of life	Quality of life	Quality of life
	Liver resection rate	Liver resection rate	Liver resection rate
	Health costs/economics	Hepatic and extrahepatic recurrence rate	Hepatic and extrahepatic recurrence rate
	Proportion of patients receiving second line treatment		Health economics
	Time to second line treatment		
Sample size accrued	364	530	209
Accrual period	November 2009–October 2014	October 2006–April 2013	May 2013–December 2014
Follow-up period	November 2014–October 2016	April 2013–April 2018	December 2014–December 2019
Randomization	1:1 with minimization	1:1 with minimization	1:1 with minimization
Minimization factors	Liver only versus extrahepatic metastases	Liver only versus extrahepatic metastases	Liver only versus extrahepatic metastases
	Extent of tumor involvement of the liver ( $\leq 25\%$ or $>25\%$ determined by CT <sup>d</sup> scan)	Extent of tumor involvement of the liver ( $\leq 25\%$ or $>25\%$ determined by CT scan) and based upon the tumor involvement groupings used by Gray et al [16]	Extent of tumor involvement of the liver ( $\leq 25\%$ or $>25\%$ determined by CT scan) and based upon the tumor involvement groupings used by Gray et al [16]
	Planned use of biological agent (from March 2011 on)	Planned use of bevacizumab with chemotherapy	Planned use of bevacizumab with chemotherapy
	Investigational center	Investigational center	Investigational center
Recruiting countries/regions	United Kingdom (England, Northern Ireland, Scotland, Wales)	Australia, Europe, Israel, New Zealand, and United States	Australia, Europe, Israel, Korea, New Zealand, Singapore, Taiwan and United States

<sup>a</sup>An open-label randomized phase III trial of 5-fluorouracil, oxaliplatin, and folinic acid +/- interventional radioembolization as first-line treatment for patients with unresectable liver-only or liver-predominant metastatic colorectal cancer.

<sup>b</sup>Randomized comparative study of FOLFOX6m plus SIR-Spheres microspheres versus FOLFOX6m alone as first-line treatment in patients with nonresectable liver metastases from primary colorectal carcinoma.

<sup>c</sup>Assessment of overall survival of FOLFOX6m plus SIR-Spheres microspheres versus FOLFOX6m alone as first-line treatment in patients with nonresectable liver metastases from primary colorectal carcinoma in a randomized clinical study.

<sup>d</sup>Computed tomography.

**Figure 1.** Schema for the FOXFIRE, SIRFLOX, and FOXFIRE-Global trials.

### Patients and Treatment

All randomized patients from the SIRFLOX, FOXFIRE, and FOXFIRE-Global clinical trials will be included in the combined analysis.

#### Inclusion Criteria

- Histologically confirmed CRC with liver-only or liver-dominant metastases not amenable to surgical resection, primary tumour in situ permitted (FOXFIRE); histologically confirmed CRC with liver-only or liver-dominant metastases (SIRFLOX); histologically confirmed adenocarcinoma of the colon or rectum with or without primary tumor in situ (FOXFIRE-Global)
- Unequivocal and measurable computed tomography (CT) evidence of liver metastases not treatable by surgical resection or local ablation with curative intent at time of trial entry
- Chemotherapy-naïve for mCRC, but previous adjuvant systemic chemotherapy for primary CRC or neoadjuvant chemoradiotherapy to the pelvis more than 6 months before recruitment is permitted (SIRFLOX, FOXFIRE-Global); eligible for systemic chemotherapy as first-line treatment for metastatic CRC (FOXFIRE)
- Additional limited extrahepatic metastases in the lung or lymph nodes permitted (SIRFLOX, FOXFIRE-Global); patients are permitted to have limited extrahepatic disease (FOXFIRE)
- Age  $\geq 18$  years
- World Health Organization performance status of 0-1
- Life expectancy  $>3$  months
- Adequate hematological, renal, and hepatic function

- Female patients must be postmenopausal or using adequate contraception if premenopausal, and male patients must be using an appropriate method of contraception if with a premenopausal partner (FOXFIRE); female patients must either be postmenopausal, sterile (surgically or chemically or radiation-induced) or if sexually active using an acceptable method of contraception, and male patients must be surgically sterile or if sexually active and have a premenopausal partner must be using an acceptable method of contraception (SIRFLOX, FOXFIRE-Global)
- Suitable for all aspects of treatment determined by clinical assessment undertaken by investigator
- Willing and able to provide written informed consent

#### FOXFIRE-Global and SIRFLOX:

- All imaging evidence used as part of the screening process must be within 28 days prior to randomization

#### Exclusion Criteria

- Evidence of ascites, cirrhosis, portal hypertension; tumour involvement of, or thrombosis leading to occlusion of the main portal vein
- Previous radiotherapy delivered to upper abdomen or upper lumbar spine (FOXFIRE); previous radiotherapy delivered to the upper abdomen (SIRFLOX); previous radiotherapy delivered to the liver (FOXFIRE-Global)
- Nonmalignant disease that would render patient ineligible at the discretion of the investigator
- Dose-limiting toxicity associated with previous 5-fluorouracil or oxaliplatin chemotherapy

- Peripheral neuropathy higher than grade 1 (National Cancer Institute–Common Terminology Criteria for Adverse Events [NCI-CTCAE] version 3)
- Pregnant or breastfeeding
- Previous chemotherapy for any malignancy; adjuvant chemotherapy for colorectal cancer is not an exclusion criterion provided that it was completed more than 6 months prior to entry into the study (SIRFLOX, FOXFIRE-Global). Previous chemotherapy for metastatic colorectal cancer; adjuvant chemotherapy for colorectal cancer is not an exclusion criterion provided that it was completed more than 6 months prior to entry into the study (FOXFIRE)
- Concurrent or prior history of cancer other than adequately treated nonmelanoma skin cancer or carcinoma in situ of the cervix (SIRFLOX, FOXFIRE-Global); other active malignancy within last 5 years excluding colorectal cancer and other nonmelanoma skin cancers (FOXFIRE)

SIRFLOX and FOXFIRE-Global:

Allergy to nonionic contrast agents

FOXFIRE only:

- Liver metastases amenable to curative resection at time of study entry
- Equivocal, immeasurable, or nonevaluable liver metastases
- Unequivocal evidence of bone metastasis

All patients received first-line chemotherapy for mCRC. In FOXFIRE, the chemotherapy received was oxaliplatin, 5-fluorouracil, and leucovorin/folic acid in the OxMdG regime [17]. In SIRFLOX and FOXFIRE-Global, the chemotherapy consisted of the same drugs in the mFOLFOX6 regime [18]. Patients were randomized 1:1 to the addition of SIRT using yttrium-90 resin microspheres, using minimization. The minimization factors are given in Table 1. Biological agents (cetuximab or bevacizumab in FOXFIRE; bevacizumab in SIRFLOX) were permitted to be added to chemotherapy at the treating investigators' discretion. Protocol treatment in each study was commenced within 28 days of randomization. Further details on randomization by minimization and treatment regimens for FOXFIRE and SIRFLOX have been published previously [13,14]. FOXFIRE-Global used the same randomization method and treatment regimen as that used for the SIRFLOX study.

In all 3 trials, patients were assessed every 2 weeks during chemotherapy treatment. In SIRFLOX and FOXFIRE-Global, patients were assessed every 12 weeks during the postprogression follow-up period. FOXFIRE patients were assessed every 8 weeks following completion of treatment up to 18 months and then every 12 weeks thereafter. In all 3 trials, patients were followed until death or for a period of at least 2 years after randomization. Patients undergoing surgical resection after trial entry were also followed up until trial closure or until death.

Screening and follow-up assessments included clinical assessment and laboratory analyses, recording concurrent medications, CT scan of the chest/abdomen/pelvis with or without magnetic resonance imaging, recording adverse events,

assessment for resection or ablation, and questionnaire-based assessments of quality of life.

## Study Outcomes

### *Primary Outcome of the Combined Analysis*

The primary outcome of OS is the time from randomization to death from any cause, with patients still alive being censored at their last known follow-up date.

### *Secondary Outcomes of the Combined Analysis*

The secondary outcomes are PFS at any site, liver-specific PFS, health-related quality of life (HRQoL), response rate, resection rate, and the safety profiles. PFS is defined as the time from randomization to radiological progression according to Response Evaluation Criteria In Solid Tumors (RECIST version 1.0) or death from any cause, whichever is sooner. Patients who are not observed to progress or die during the course of the trial will be censored at last known progression-free follow-up date. Patients who withdraw from study treatment prior to documented progression will be censored at the time they commence nonstudy treatment. Patients who become eligible for resection will be considered as still being on study until progression is documented or last follow-up. Scans and tumor response will be centrally reviewed in FOXFIRE and SIRFLOX.

Liver-specific PFS is defined as the time from randomization to radiological progression in the liver (hepatic progression) according to RECIST version 1.0. Progression outside the liver (extrahepatic progression) and deaths prior to progression will be considered as competing risks for failure in the liver. Hepatic progression will be assumed to have occurred immediately before extrahepatic progression in patients who have identical hepatic and extrahepatic progression dates. Patients who withdraw from study treatment prior to any documented progression will be censored at the time they commence nonstudy treatment. Patients who become eligible for resection will be considered as still being on study until progression is documented or last follow-up.

HRQoL will be assessed using the EuroQol 5 dimensions questionnaire (EQ-5D). The EQ-5D comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each of the 5 dimensions is scored, generating a profile. A single index score or utility value, representing population-derived preferences for different health states, will be attached to each profile.

The response rate (objective response) is defined as the number of patients achieving a complete or partial response according to RECIST version 1.0 divided by the number of patients in each treatment arm. Early death by any cause and unknown responses will be included in the denominator. Response will be assessed over 2 time periods: within 12 months of randomization and over follow-up.

The resection rate in each treatment arm is defined as the number of patients undergoing resection of their liver metastases divided by the number of patients randomized in each arm. Patients undergoing treatment are assessed by an experienced liver multidisciplinary team or equivalent for eligibility for resection at the discretion of the treating physician.

The safety profile is assessed by the collection of adverse events (AEs) and serious adverse events (SAEs) at any time during treatment with grading using the NCI-CTCAE version 3.

### Sample Size Calculation

For the primary combined OS analysis, the FOXFIRE study protocol details a calculated 1075 patients required using a protocol-specified hazard ratio (HR) of 0.8, a 36-month accrual period, and 18-month minimum follow-up with 2-sided 5% significance, 80% power, and allowing for noncompliance. A total of 710 deaths are expected. The required sample size had been previously calculated to be 1022 [13] but was updated to reflect an estimated increase in median OS in the control group. As the intervention is a local treatment to the liver only, it is anticipated that even if there is no OS benefit in the whole population, a demonstrated survival benefit in the liver-only subgroup would be clinically meaningful and could change practice. It is anticipated that, with a 6-month increase in OS in the SIRT treated liver-only patients compared to those randomized to chemotherapy only, this would require 463 events in the liver-only subgroup.

### Closure of Study

The final analysis will be undertaken when a minimum of 710 deaths overall and 463 deaths in the liver-only subgroup have been observed in the pooled dataset and there has been a minimum follow-up of 2 years since the last patient was randomized into the 3 trials.

### Data Monitoring Committee and Interim Analyses

The independent data and safety monitoring committee (IDSMC) consisted of the same representatives for the FOXFIRE, SIRFLOX, and FOXFIRE-Global clinical trials. Formal interim monitoring of the accumulating data was performed at regular intervals (approximately every 6 months) by the IDSMC for each trial separately. This information included results from other relevant trials but not the analysis of primary or secondary objectives or outcomes by treatment groups apart from the prespecified interim analyses. As part of the review, the IDSMC was asked to justify continued recruitment of further patients or further follow-up. The IDSMC advised on the frequency of future reviews of the data on the basis of accrual and event rates.

The IDSMC reviewed the combined safety data from FOXFIRE and SIRFLOX at the interim analyses. The following planned interim analyses were undertaken using combined data from the FOXFIRE and SIRFLOX trials:

- Analysis of toxicity and safety: 8 months after at least 80 patients were randomized in total (a minimum of 40 per trial)
- Analysis of toxicity and safety: 8 months after at least 300 patients were randomized in total (a minimum of 120 patients per trial)

The 3 clinical trials that constitute this MA were conducted in accordance with the Declaration of Helsinki and current Good Clinical Practice guidelines, and all participating centers obtained the relevant ethics committee approval before patient enrollment. FOXFIRE was approved by the National Research

Ethics Service Committee South Central – Berkshire Research Ethics Committee reference 09/H0505/1 and sponsored by the University of Oxford. SIRFLOX and FOXFIRE-Global were approved by the relevant ethics committees for each center and sponsored by Sirtex Technology Pty Ltd.

### Statistical Analysis

#### *Descriptive Summaries*

Summaries of baseline factors, including minimization factors, and percentages of missing data will be reported. Losses to follow-up will be reported for each trial and combined. Median follow-up time will be calculated using the reverse Kaplan-Meier method. Dose of trial-specific treatment delivered and treatment received subsequent-to-trial treatment will be described.

#### *Efficacy*

All efficacy analyses will be performed on an intention-to-treat (ITT) basis. OS and PFS estimates will be obtained using Kaplan-Meier survival curves, unadjusted log-rank tests, and survival models. A 2-stage inverse-variance weighted IPD-MA will be performed for both OS and PFS, with the first stage consisting of trial-specific analyses to obtain efficacy estimates (HRs) and the second stage being a pooled analysis of the separate trial-specific HRs. As a sensitivity analysis, a 1-stage IPD-MA using regression models stratified by study will be performed to confirm the results obtained from the 2-stage IPD-MA. For each outcome, multivariable models will be used in the 1-stage IPD-MA to account for baseline covariates.

Liver-specific PFS will be analyzed using cumulative incidence curves, Gray's test, and competing risks regression. This analysis will be performed on the pooled dataset with models stratified by trial. For OS, PFS, and liver-specific PFS, the potential treatment benefit in those patients who present with disease confined to the liver will be investigated. This prespecified subgroup analysis will be performed on the pooled dataset. The analysis strategy will include calculating HR for the effect of treatment in the liver-only subgroup using survival models stratified by trial.

A separate landmark analysis of OS will start at the 15-month time point (after randomization) and therefore exclude those who have died/withdrawn within 15 months of randomization. This time point has previously been considered of value in clinical trials of the treatment of mCRC [19]. Based on expert opinion, it is anticipated that 15 months from baseline allows sufficient time for events to occur in those with both diagnosed extrahepatic metastases and subclinical extrahepatic metastases at baseline, and therefore this analysis may be of value in detecting any differential survival impact of SIRT in patients with liver-only metastases.

The EQ-5D data will be merged across all 3 trials and summary data prepared on the mean EQ-5D utility score in each trial arm by time period, with appropriate tests for difference. Resection rate and response rate will be analyzed using chi-square tests and odds ratios (ORs) for the individual trials and a 2-stage IPD-MA.

## Safety

Safety analyses will be performed on patients who received at least 1 dose of chemotherapy in either arm and on an as-treated basis (safety population). AEs experienced up to 28 days after the end of trial treatment or 7 months postrandomization, whichever was earlier, will be included. Descriptive summaries of the frequency and severity of AEs and the numbers of patients experiencing AEs of grade 3 or higher between treatment arms will be presented overall and by system organ class. The Medical Dictionary for Regulatory Activities version 16.1 is used to categorize the AEs. Univariate comparisons will be made.

All hypothesis tests will be 2-sided. A significance level of .05 will be used to indicate statistical significance. No missing data imputation is intended. Missing days in dates may be appropriately imputed.

## Results

Data from the final data lock will become available in January 2017. Data analysis will take place in 2017 with results being disseminated via peer-reviewed journals in 2017 and 2018.

## Discussion

Optimizing outcomes of treatment in patients with nonresectable liver metastases was identified in an international consensus expert statement as a key clinical need to be addressed [20]. This is the first extensive investigation of SIRT in the first-line setting for liver metastases from mCRC adequately powered to address an overall survival endpoint.

This prospective MA of 3 phase III studies will provide comprehensive evidence of the safety and potential efficacy of SIRT in the first-line setting for patients with liver metastases from mCRC. The results of the SIRFLOX trial published so far have suggested that the addition of SIRT to chemotherapy can improve liver-specific PFS [15]. The number of patients included in this combined analysis and the long-term follow-up, unprecedented in the field of interventional oncology, will provide adequate power to address a survival endpoint.

Although the SIRFLOX trial reported that liver-specific PFS was longer in the SIRT arm than in the control arm, the PFS at any site was similar between the SIRT arm and the control arm [15]. This can be accounted for by the fact that SIRT is a locoregional treatment to the liver only and therefore will not influence the progression of extrahepatic metastases or extrahepatic subclinical micrometastases.

It is generally accepted that successful resection of liver metastases correlates with improved overall survival, particularly in the context of neoadjuvant or adjuvant chemotherapy [21,22]. Surgery and perioperative chemotherapy are therefore routinely offered to patients with mCRC if the liver metastases are resectable. Similarly, the addition of radiofrequency ablation of liver metastases to standard chemotherapy appears to improve clinical outcomes for patients compared to those patients receiving standard chemotherapy alone [23,24]. These findings with liver-directed therapies suggest that improvement of liver-specific PFS in patients with liver metastases may correlate to improvement in OS, an important hypothesis to be tested for SIRT for the first time in this combined MA of the SIRFLOX, FOXFIRE, and FOXFIRE-Global trials.

The use of an IPD rather than an aggregate data approach to systematic review and MA of randomized controlled trials enables the standardization of outcomes across trials and detailed data checking, providing a more in-depth exploration and more robust MA results [25]. The proposed MA, by prospectively combining IPD from 3 trials, goes beyond classical MA aims and overrides drawbacks from single trials. The prospective approach allows for consistent inclusion and exclusion criteria between studies. The statistical analysis is going to be standardized across studies, and using IPD-MA will provide sufficient statistical power to draw conclusions from subgroup analyses that are generally undermined by low sample size. The use of the 2-stage approach for the main analyses of OS and PFS is prespecified, as the 2-stage approach might produce different parameter estimates to the 1-stage approach, although the estimates are usually similar [26,27].

The results from the combined analysis of the SIRFLOX, FOXFIRE, and FOXFIRE-Global trials will provide valuable clinical information on the efficacy and toxicity profile of SIRT combined with chemotherapy as a first-line regimen for liver metastases from mCRC that will guide clinicians in the use of this technology to treat their patients. The IPD-MA will allow comparisons of less common AEs that would not be possible in a smaller population. Furthermore, this prospective MA provides sufficient power to determine whether SIRT provides a significant survival benefit for patients with metastases confined to the liver and no clinically detectable extrahepatic disease, an important research question among clinicians treating mCRC. When reported, the results of this combined analysis will define the use of SIRT in the treatment of mCRC.

## Acknowledgments

The FOXFIRE trial was developed by the National Cancer Research Institute Colorectal Clinical Study Group and is sponsored by the University of Oxford. It is supported by the Bobby Moore Fund of Cancer Research United Kingdom (Clinical Trials Awards and Advisory Committee reference number CRUK/A16630), an educational grant from Sirtex Medical Ltd, and by the National Institute for Health Research Biomedical Research Center Oxford. The SIRFLOX and FOXFIRE-Global studies are sponsored by Sirtex Technology Pty Ltd.

The FOXFIRE Trial Management and Quality Assurance Group: Adil Al-Nahas, Dave Berry, Ian Chau, Luise Dunham, David Kerr, Nas Khan, Val Lewington, Rachel Midgley, Bruno Morgan, Sarah Pearson, Anne Roberts, Will Steward, Paul Tait, Greg Wilson, Andy Wotherspoon.

FOXFIRE Health Economists: Alastair Gray, Jane Wolstenholme.

The FOXFIRE Study Group: Richard Adams, Andrew Bateman, Claire Blesing, Ewan Brown, Ian Chau, Sebastian Cummins, David Cunningham, Stephen Falk, Maher Hadaki, Marcia Hall, Tamas Hickish, Joanne Hornbuckle, Fiona Lofts, Sarah Lowndes, Astrid Mayer, Matthew Metcalfe, Gary Middleton, Jamie Mills, Amir Montazeri, Rebecca Muirhead, Andreas Polychronis, Colin Purcell, Paul Ross, Liz Sherwin, David Smith, Rubin Soomal, Daniel Swinson, Axel Walther, Andrew Weaver, Charles Wilson, Greg Wilson. We would also like to thank the University of Oxford statisticians Susan Dutton and Peter Dutton for their contributions to the FOXFIRE study.

The SIRFLOX and FOXFIRE-Global Study Group: Steven Ades, Morteza Aghmesheh, Pradip Amin, Bruna Angelelli, Miklos Auber, Jacques Balosso, Alex Beny, Daniel Bloomgarden, Patrick Boland, Eveline Boucher, Christoph Bremer, Michael Brown, Harald-Robert Bruch, James Bui, Matthew Burge, Giuseppe Cardaci, James Carlisle, Ruiz Casado, Yi-Jen Chen, Patrick Chevallier, Michael Chuong, Stephen Clarke, Prasad Cooray, Andrew Coveler, Michel Craninx, Thierry Delanoit, Amélie Deleporte, Kyran Dowling, Aurelie Durand, Paul Eliadis, Francis Facchini, Kynan Feeney, Thomas Ferguson, Michel Ferrante, Aurelie Ferru, Michael Findlay, Maria Fragoso, Gary Frenette, Jacob Frick, Vinod Ganju, Michael Garofalo, Karen Geboes, Gerald Gehbauer, Benjamin George, Ravit Geva, Michael Gordon, Cristina Granetto, Kate Gregory, Seza Gulec, Pascal Hammel, James Hannigan, Norman Heching, Volker Heinemann, Thomas Helmberger, Alain Hendlisz, Koen Hendrickx, Matthew Holtzman, Ayala Hubert, Richard Isaacs, Christopher Jackson, Philip James, Adeel Kaiser, Chris Karapetis, Andreas Kaubisch, Yeul Hong Kim, Yon-Dschun Ko, Todd Kooy, Hendrik Kröning, Frank Lammert, Jin Tung Liang, Winston Liauw, Lionel Lim, Yoo Joo Lim, Jin Hwang Liu, Samy Louafi, Marc de Man, Jeffrey Margolis, Robert Martin, Andrea Martoni, Gavin Marx, Marco Matos, Els Monsaert, Veerle Moons, Stefania Mosconi, Louise Nott, Arnd Nusch, Anne O'Donnell, Howard Ozer, Siddarth Padia, Nick Pavlakis, Marc Peeters, David Perez, Stefan Pluntke, Marc Polus, Alex Powell, Marc Pracht, Timothy Price, Jorge Ramon, David Ransom, Christine Rebuschung, Jens Rieke, Karsten Ridwelski, Hanno Riess, Jorge Ramon Riera, William Rilling, Bridget Robinson, Javier Rodríguez, Federico Sanchez, Tilmann Sauerbruch, Michael Savin, Klemens Scheidhauer, Elyse Schneiderman, Grant Seeger, Eva Segelov, Einat Shaham Schmueli, Adi Shani, Jenny Shannon, Navesh Sharma, Stephen Shibata, Nimit Singhal, Denis Smith, Randall Smith, Salomon Stemmer, Oliver Stötzer, Andrew Strickland, Julien Taieb, Iain Tan, Klaus Tatsch, Eric Terrebbonne, Thomas Tichler, Antonio Trogu, Craig Underhill, Daniel Van Daele, Ursula Vehling-Kaiser, Ruth Vera-Garcia, Caterina Vivaldi, Thomas Vogl, Euan Walpole, Eric Wang, Mark Westcott, Samuel Whiting, Ido Wolf.

The authors acknowledge Bruce Gray for his involvement in the development of the initial SIRFLOX protocol and the editorial assistance provided by Martin Gilmour and Thierry Delteil of ESP Bioscience (Crowthorne, United Kingdom) during the preparation of this manuscript.

---

## Authors' Contributions

RAS and HSW conceived the FOXFIRE study and secured the funding for the investigator-initiated study. SBL and JM provided statistical advice. All authors read and approved the final draft of the manuscript for submission. PG, VG, and GVH were substantially involved in the conception and design of the SIRFLOX and FOXFIRE-Global studies. EAF coordinated the FOXFIRE study during the patient follow-up period. All authors were involved in critically reviewing the manuscript for important intellectual content, and all authors read and approved the final draft of the manuscript for submission.

---

## Conflicts of Interest

RAS has received research funding, honoraria, and consultancy fees from Sirtex Medical Ltd. PG has received honoraria from Sirtex for participation in advisory boards and for giving presentations. VG and GVH have received compensation for participation in advisory committees from Sirtex. PSV, JM, HSW, EAF, and SBL declare no competing interests.

---

## References

1. Surveillance, Epidemiology, and End Results Stat Fact Sheets: Colon and Rectum Cancer, 2003-2009. 2013. URL: <https://seer.cancer.gov/statfacts/html/colorect.html> [accessed 2016-12-15] [[WebCite Cache ID 6mmB3DsTx](#)]
2. Abbas S, Lam V, Hollands M. Ten-year survival after liver resection for colorectal metastases: systematic review and meta-analysis. *ISRN Oncol* 2011 [[FREE Full text](#)] [doi: [10.5402/2011/763245](https://doi.org/10.5402/2011/763245)] [Medline: [22091431](#)]
3. Helling TS, Martin M. Cause of death from liver metastases in colorectal cancer. *Ann Surg Oncol* 2014 Feb;21(2):501-506. [doi: [10.1245/s10434-013-3297-7](https://doi.org/10.1245/s10434-013-3297-7)] [Medline: [24081807](#)]
4. Rothbarth J, van de Velde CJH. Treatment of liver metastases of colorectal cancer. *Ann Oncol* 2005;16 Suppl 2:ii144-ii149 [[FREE Full text](#)] [doi: [10.1093/annonc/mdi702](https://doi.org/10.1093/annonc/mdi702)] [Medline: [15958446](#)]

5. Berber E, Pelley R, Siperstein AE. Predictors of survival after radiofrequency thermal ablation of colorectal cancer metastases to the liver: a prospective study. *J Clin Oncol* 2005 Mar 01;23(7):1358-1364. [doi: [10.1200/JCO.2005.12.039](https://doi.org/10.1200/JCO.2005.12.039)] [Medline: [15684312](https://pubmed.ncbi.nlm.nih.gov/15684312/)]
6. Navarra G, Ayav A, Weber J, Jensen SL, Smadga C, Nicholls JP, et al. Short- and long-term results of intraoperative radiofrequency ablation of liver metastases. *Int J Colorectal Dis* 2005 Nov;20(6):521-528. [doi: [10.1007/s00384-005-0743-4](https://doi.org/10.1007/s00384-005-0743-4)] [Medline: [15864606](https://pubmed.ncbi.nlm.nih.gov/15864606/)]
7. Van Cutsem E, Nordlinger B, Adam R, Köhne C, Pozzo C, Poston G, European Colorectal Metastases Treatment Group. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. *Eur J Cancer* 2006 Sep;42(14):2212-2221. [doi: [10.1016/j.ejca.2006.04.012](https://doi.org/10.1016/j.ejca.2006.04.012)] [Medline: [16904315](https://pubmed.ncbi.nlm.nih.gov/16904315/)]
8. Jones RP, Poston GJ. Resection of liver metastases in colorectal cancer in the era of expanding systemic therapy. *Annu Rev Med* 2016 Sep 28. [doi: [10.1146/annurev-med-062415-093510](https://doi.org/10.1146/annurev-med-062415-093510)] [Medline: [27686016](https://pubmed.ncbi.nlm.nih.gov/27686016/)]
9. Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Mahoney MR, Dakhil SR, et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. *J Clin Oncol* 2005 Dec 20;23(36):9243-9249. [doi: [10.1200/JCO.2005.07.740](https://doi.org/10.1200/JCO.2005.07.740)] [Medline: [16230673](https://pubmed.ncbi.nlm.nih.gov/16230673/)]
10. Folprecht G, Grothey A, Alberts S, Raab H, Köhne C. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. *Ann Oncol* 2005 Aug;16(8):1311-1319 [FREE Full text] [doi: [10.1093/annonc/mdi246](https://doi.org/10.1093/annonc/mdi246)] [Medline: [15870084](https://pubmed.ncbi.nlm.nih.gov/15870084/)]
11. Nicolay NH, Berry DP, Sharma RA. Liver metastases from colorectal cancer: radioembolization with systemic therapy. *Nat Rev Clin Oncol* 2009 Dec;6(12):687-697. [doi: [10.1038/nrclinonc.2009.165](https://doi.org/10.1038/nrclinonc.2009.165)] [Medline: [19884901](https://pubmed.ncbi.nlm.nih.gov/19884901/)]
12. Wang LM, Jani AR, Hill EJ, Sharma RA. Anatomical basis and histopathological changes resulting from selective internal radiotherapy for liver metastases. *J Clin Pathol* 2013 Mar;66(3):205-211 [FREE Full text] [doi: [10.1136/jclinpath-2012-201231](https://doi.org/10.1136/jclinpath-2012-201231)] [Medline: [23162108](https://pubmed.ncbi.nlm.nih.gov/23162108/)]
13. Dutton SJ, Kenealy N, Love SB, Wasan HS, Sharma RA, FOXFIRE Protocol Development Group and the NCRI Colorectal Clinical Study Group. FOXFIRE protocol: an open-label, randomised, phase III trial of 5-fluorouracil, oxaliplatin and folinic acid (OxMdG) with or without interventional Selective Internal Radiation Therapy (SIRT) as first-line treatment for patients with unresectable liver-only or liver-dominant metastatic colorectal cancer. *BMC Cancer* 2014 Jul 09;14:497 [FREE Full text] [doi: [10.1186/1471-2407-14-497](https://doi.org/10.1186/1471-2407-14-497)] [Medline: [25011439](https://pubmed.ncbi.nlm.nih.gov/25011439/)]
14. Gibbs P, GebSKI V, Van Buskirk M, Thurston K, Cade DN, Van Hazel GA. Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX study. *BMC Cancer* 2014 Dec 01;14:897 [FREE Full text] [doi: [10.1186/1471-2407-14-897](https://doi.org/10.1186/1471-2407-14-897)] [Medline: [25487708](https://pubmed.ncbi.nlm.nih.gov/25487708/)]
15. van Hazel GA, Heinemann V, Sharma NK, Findlay MPN, Ricke J, Peeters M, et al. SIRFLOX: randomized phase III trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer. *J Clin Oncol* 2016 May 20;34(15):1723-1731. [doi: [10.1200/JCO.2015.66.1181](https://doi.org/10.1200/JCO.2015.66.1181)] [Medline: [26903575](https://pubmed.ncbi.nlm.nih.gov/26903575/)]
16. Gray B, Van Hazel G, Hope M, Burton M, Moroz P, Anderson J, et al. Randomised trial of SIR-Spheres plus chemotherapy versus chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. *Ann Oncol* 2001 Dec;12(12):1711-1720 [FREE Full text] [Medline: [11843249](https://pubmed.ncbi.nlm.nih.gov/11843249/)]
17. Shimizu T, Satoh T, Tamura K, Ozaki T, Okamoto I, Fukuoka M, et al. Oxaliplatin/fluorouracil/leucovorin (FOLFOX4 and modified FOLFOX6) in patients with refractory or advanced colorectal cancer: post-approval Japanese population experience. *Int J Clin Oncol* 2007 Jun;12(3):218-223. [doi: [10.1007/s10147-007-0658-x](https://doi.org/10.1007/s10147-007-0658-x)] [Medline: [17566846](https://pubmed.ncbi.nlm.nih.gov/17566846/)]
18. Braun MS, Adab F, Bradley C, McAdam K, Thomas G, Wadd NJ, et al. Modified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancer. *Br J Cancer* 2003 Oct 06;89(7):1155-1158 [FREE Full text] [doi: [10.1038/sj.bjc.6601237](https://doi.org/10.1038/sj.bjc.6601237)] [Medline: [14520437](https://pubmed.ncbi.nlm.nih.gov/14520437/)]
19. Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Petrelli NJ, Colangelo LH, et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. *J Clin Oncol* 2011 Jan 01;29(1):11-16 [FREE Full text] [doi: [10.1200/JCO.2010.30.0855](https://doi.org/10.1200/JCO.2010.30.0855)] [Medline: [20940184](https://pubmed.ncbi.nlm.nih.gov/20940184/)]
20. Clary BM, Grothey A, Kopetz S, Marsh RDW. Systemic cytotoxic and biologic therapies for colorectal cancer liver metastases: expert consensus statement. *HPB (Oxford)* 2013 Feb;15(2):116-118 [FREE Full text] [doi: [10.1111/j.1477-2574.2012.00598.x](https://doi.org/10.1111/j.1477-2574.2012.00598.x)] [Medline: [23297722](https://pubmed.ncbi.nlm.nih.gov/23297722/)]
21. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, EORTC Gastro-Intestinal Tract Cancer Group, Cancer UK, Arbeitsgruppe Lebermetastasen und Tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO), Australasian Gastro-Intestinal Trials Group (AGITG), Fédération Francophone de Cancérologie Digestive (FFCD). Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. *Lancet Oncol* 2013 Nov;14(12):1208-1215. [doi: [10.1016/S1470-2045\(13\)70447-9](https://doi.org/10.1016/S1470-2045(13)70447-9)] [Medline: [24120480](https://pubmed.ncbi.nlm.nih.gov/24120480/)]
22. Bokemeyer C, Van Cutsem E, Rougier P, Ciardiello F, Heeger S, Schlichting M, et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. *Eur J Cancer* 2012 Jul;48(10):1466-1475. [doi: [10.1016/j.ejca.2012.02.057](https://doi.org/10.1016/j.ejca.2012.02.057)] [Medline: [22446022](https://pubmed.ncbi.nlm.nih.gov/22446022/)]

23. Ruers T, Punt C, Van Coevorden F, Pierie JPEN, Borel-Rinkes I, Ledermann JA, EORTC Gastro-Intestinal Tract Cancer Group, Arbeitsgruppe Lebermetastasen und tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO), National Cancer Research Institute Colorectal Clinical Study Group (NCRI CCSG). Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004). *Ann Oncol* 2012 Oct;23(10):2619-2626 [[FREE Full text](#)] [doi: [10.1093/annonc/mds053](https://doi.org/10.1093/annonc/mds053)] [Medline: [22431703](https://pubmed.ncbi.nlm.nih.gov/22431703/)]
24. Ruers T, Cornelis J, Punt C, Van Coevorden F, Pierie J, Rinkes I, et al. Radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM): Long-term survival results of a randomized phase II study of the EORTC-NCRI CCSG-ALM Intergroup 40004 (CLOCC). *J Clin Oncol* 2015;33(Suppl):A3501.
25. Tierney JF, Vale C, Riley R, Smith CT, Stewart L, Clarke M, et al. Individual participant data (IPD) meta-analyses of randomised controlled trials: guidance on their use. *PLoS Med* 2015 Jul;12(7):e1001855 [[FREE Full text](#)] [doi: [10.1371/journal.pmed.1001855](https://doi.org/10.1371/journal.pmed.1001855)] [Medline: [26196287](https://pubmed.ncbi.nlm.nih.gov/26196287/)]
26. Debray TPA, Moons KGM, Abo-Zaid GMA, Koffijberg H, Riley RD. Individual participant data meta-analysis for a binary outcome: one-stage or two-stage? *PLoS One* 2013;8(4):e60650 [[FREE Full text](#)] [doi: [10.1371/journal.pone.0060650](https://doi.org/10.1371/journal.pone.0060650)] [Medline: [23585842](https://pubmed.ncbi.nlm.nih.gov/23585842/)]
27. Stewart GB, Altman DG, Askie LM, Duley L, Simmonds MC, Stewart LA. Statistical analysis of individual participant data meta-analyses: a comparison of methods and recommendations for practice. *PLoS One* 2012;7(10):e46042 [[FREE Full text](#)] [doi: [10.1371/journal.pone.0046042](https://doi.org/10.1371/journal.pone.0046042)] [Medline: [23056232](https://pubmed.ncbi.nlm.nih.gov/23056232/)]

## Abbreviations

**AE:** adverse event

**CRC:** colorectal cancer

**CT:** computed tomography

**EQ-5D:** EuroQol 5 dimensions questionnaire

**FOLFOX:** modified fluorouracil, leucovorin, and oxaliplatin regimen

**FOXFIRE:** An open-label randomized phase III trial of 5-fluorouracil, oxaliplatin, and folinic acid +/- interventional radioembolization as first-line treatment for patients with unresectable liver-only or liver-predominant metastatic colorectal cancer

**FOXFIRE-Global:** Assessment of overall survival of FOLFOX6m plus SIR-Spheres microspheres versus FOLFOX6m alone as first-line treatment in patients with nonresectable liver metastases from primary colorectal carcinoma in a randomized clinical study

**HR:** hazard ratio

**HRQoL:** health-related quality of life

**IDSMC:** independent data and safety monitoring committee

**IPD:** individual participant data

**IPD-MA:** Individual participant data meta-analysis

**ITT:** intention-to-treat

**MA:** meta-analysis

**mCRC:** metastatic colorectal cancer

**NCI-CTCAE:** National Cancer Institute–Common Terminology Criteria for Adverse Events

**OR:** odds ratio

**OS:** overall survival

**PFS:** progression-free survival

**RECIST:** Response Evaluation Criteria In Solid Tumors

**SAE:** serious adverse events

**SIRFLOX:** Randomized comparative study of FOLFOX6m plus SIR-Spheres microspheres versus FOLFOX6m alone as first-line treatment in patients with nonresectable liver metastases from primary colorectal carcinoma

**SIRT:** selective internal radiation therapy

*Edited by G Eysenbach; submitted 20.12.16; peer-reviewed by A Kennedy, T Helmberger; comments to author 11.01.17; revised version received 19.01.17; accepted 21.01.17; published 28.03.17*

*Please cite as:*

*Virdee PS, Moschandreas J, GebSKI V, Love SB, Francis EA, Wasan HS, van Hazel G, Gibbs P, Sharma RA  
Protocol for Combined Analysis of FOXFIRE, SIRFLOX, and FOXFIRE-Global Randomized Phase III Trials of Chemotherapy +/-  
Selective Internal Radiation Therapy as First-Line Treatment for Patients With Metastatic Colorectal Cancer*

*JMIR Res Protoc 2017;6(3):e43*

*URL: <http://www.researchprotocols.org/2017/3/e43/>*

*doi: [10.2196/resprot.7201](https://doi.org/10.2196/resprot.7201)*

*PMID: [28351831](https://pubmed.ncbi.nlm.nih.gov/28351831/)*

©Pradeep S Virdee, Joanna Moschandreas, Val GebSKI, Sharon B Love, E Anne Francis, Harpreet S Wasan, Guy van Hazel, Peter Gibbs, Ricky A Sharma. Originally published in JMIR Research Protocols (<http://www.researchprotocols.org>), 28.03.2017. This is an open-access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Research Protocols, is properly cited. The complete bibliographic information, a link to the original publication on <http://www.researchprotocols.org>, as well as this copyright and license information must be included.